© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Alector, Inc. (ALEC) stock declined over -5.73%, trading at $2.14 on NASDAQ, down from the previous close of $2.27. The stock opened at $2.22, fluctuating between $2.00 and $2.24 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | 2.22 | 2.24 | 2.00 | 2.14 | 3.78M |
| Sep 09, 2026 | 2.47 | 2.47 | 2.25 | 2.27 | 505.6K |
| Sep 08, 2026 | 2.38 | 2.61 | 2.33 | 2.47 | 915.27K |
| Sep 04, 2026 | 2.52 | 2.58 | 2.44 | 2.46 | 496.6K |
| Sep 03, 2026 | 2.70 | 2.75 | 2.44 | 2.51 | 2.68M |
| Sep 02, 2026 | 2.40 | 2.76 | 2.40 | 2.72 | 1.67M |
| Sep 01, 2026 | 2.24 | 2.49 | 2.22 | 2.40 | 482.25K |
| Aug 31, 2026 | 2.32 | 2.35 | 2.23 | 2.26 | 610.06K |
| Aug 28, 2026 | 2.39 | 2.44 | 2.32 | 2.34 | 542.22K |
| Aug 27, 2026 | 2.44 | 2.50 | 2.39 | 2.39 | 706.68K |
| Aug 26, 2026 | 2.38 | 2.52 | 2.26 | 2.46 | 995.46K |
| Aug 25, 2026 | 2.32 | 2.46 | 2.28 | 2.36 | 556.53K |
| Aug 24, 2026 | 2.36 | 2.47 | 2.29 | 2.30 | 738.14K |
| Aug 21, 2026 | 2.28 | 2.37 | 2.20 | 2.36 | 728.09K |
| Aug 20, 2026 | 2.40 | 2.46 | 2.19 | 2.26 | 662.21K |
| Aug 19, 2026 | 2.25 | 2.53 | 2.15 | 2.43 | 3.76M |
| Aug 18, 2026 | 2.04 | 2.30 | 2.04 | 2.21 | 4.77M |
| Aug 17, 2026 | 1.91 | 2.09 | 1.90 | 2.05 | 913.8K |
| Aug 14, 2026 | 2.04 | 2.07 | 1.95 | 1.96 | 596.37K |
| Aug 13, 2026 | 2.15 | 2.15 | 1.98 | 2.04 | 1.29M |
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
| Employees | 103 |
| Beta | 0.58 |
| Sales or Revenue | $97.06M |
| 5Y Sales Change% | 1.863% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |